Splenz Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 15-11-2024
- Paid Up Capital ₹ 2.00 M
as on 15-11-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.99 M
as on 15-11-2024
- Satisfied Charges ₹ 5.00 M
as on 15-11-2024
- Revenue 9.45%
(FY 2023)
- Profit 16.54%
(FY 2023)
- Ebitda 26.14%
(FY 2023)
- Net Worth 18.99%
(FY 2023)
- Total Assets 11.12%
(FY 2023)
About Splenz Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹5.99 M. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ashish Bhagat and Jitendra Fasate serve as directors at the Company.
- CIN/LLPIN
U52599PN2014PTC151314
- Company No.
151314
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 May 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Splenz Pharmaceuticals Private Limited offer?
Splenz Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Gastrointestinal Drugs, Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Protein Powder, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at Splenz Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Bhagat  | Director | 23-Sep-2015 | Current |
| Jitendra Fasate | Director | 23-Sep-2015 | Current |
Financial Performance of Splenz Pharmaceuticals.
Splenz Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.45% increase. The company also saw a substantial improvement in profitability, with a 16.54% increase in profit. The company's net worth Soared by an impressive increase of 18.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Splenz Pharmaceuticals?
In 2022, Splenz Pharmaceuticals had a promoter holding of 86.00% and a public holding of 14.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The South Indian Bank Limited Creation Date: 03 Jan 2020 | ₹5.99 M | Open |
Others Creation Date: 06 Dec 2014 | ₹5.00 M | Satisfied |
How Many Employees Work at Splenz Pharmaceuticals?
Unlock and access historical data on people associated with Splenz Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Splenz Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Splenz Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
